SCHEDULE 13D/A: Fresenius SE & Co. KGaA Executes Strategic Portfolio Optimization with Fresenius Medical Care AG Share Placement and Exchangeable Bond Offering

Fresenius SE & Co. KGaA is strategically reducing its stake in Fresenius Medical Care AG through a share placement and the issuance of exchangeable bonds, aiming for portfolio optimization and enhanced financial stability.

Summary

• Fresenius SE & Co. KGaA (Fresenius KGaA) has filed an Amendment No. 10 to its Schedule 13D, detailing significant transactions related to its beneficial ownership in Fresenius Medical Care AG (the Company).
• On March 3, 2025, Fresenius KGaA entered into agreements for a private placement of shares and issuance of exchangeable bonds of Fresenius Medical Care AG to institutional investors.
• The Share Placement involves the sale of 10.6 million ordinary shares of Fresenius Medical Care AG at a price of EUR 44.50 (approximately $46.73) per share, expected to generate gross proceeds of EUR 471,700,000.
• Concurrently, Fresenius KGaA will issue EUR 600 million in aggregate principal amount of non-interest bearing exchangeable bonds, maturing on March 11, 2028, with an exchange price of EUR 57.85.
• These transactions are part of Fresenius KGaA's '#FutureFresenius strategy,' aimed at optimizing its investment portfolio, achieving structural simplification, and aligning with the previously disclosed deconsolidation of Fresenius Medical Care AG.
• The primary objectives are to enhance Fresenius KGaA's strategic flexibility, strengthen its balance sheet, and reduce leverage.
• Following the completion of these transactions, Fresenius KGaA will remain the largest shareholder of Fresenius Medical Care AG, retaining beneficial ownership of over 25% of the Company's shares.
• Fresenius KGaA has committed to a 180-day lock-up period, subject to customary exceptions, restricting further dispositions of Fresenius Medical Care AG shares.
• Prior to these transactions, Fresenius KGaA beneficially owned 94,380,382 shares, representing approximately 32.2% of Fresenius Medical Care AG's outstanding voting shares (based on 293,413,449 shares outstanding as of February 13, 2025).

Sentiment

Score: 8

Explanation: The strategic divestment and capital raise are presented as proactive steps to optimize the portfolio, simplify structure, strengthen the balance sheet, and reduce leverage, which are generally positive financial and strategic moves for the parent company. The retention of a significant stake (over 25%) in Fresenius Medical Care AG also suggests continued strategic interest.

Positives

• The transactions are part of a clear strategic initiative ('#FutureFresenius strategy') to optimize Fresenius KGaA's portfolio and achieve structural simplification.
• The capital raised through the share placement (EUR 471.7 million) and exchangeable bonds (EUR 600 million) is intended to strengthen the balance sheet and reduce leverage for Fresenius KGaA.
• The move enhances Fresenius KGaA's strategic flexibility by streamlining its investment holdings.
• Fresenius KGaA will maintain a significant stake (over 25%) in Fresenius Medical Care AG, ensuring continued influence as the largest shareholder.
• The successful execution of these private placements indicates market confidence in Fresenius KGaA's strategic direction and the value of Fresenius Medical Care AG's shares.

Negatives

• The transactions result in a reduction of Fresenius KGaA's direct ownership stake in Fresenius Medical Care AG from 32.2% to over 25%.
• The issuance of exchangeable bonds introduces potential future dilution for existing Fresenius Medical Care AG shareholders if the bonds are converted into shares.
• A 180-day lock-up period restricts Fresenius KGaA's ability to sell additional shares of Fresenius Medical Care AG, limiting immediate liquidity from this asset.

Risks

• Future market conditions or legal and regulatory requirements could influence Fresenius KGaA's ability or decision to further reduce its holdings in Fresenius Medical Care AG.
• The occurrence of a 'Delisting Event' (e.g., shares ceasing to be listed or trading suspension) or a 'Change of Control Event' (e.g., change in Fresenius KGaA's control combined with a ratings downgrade) could trigger a put option for bondholders, potentially requiring early redemption of the exchangeable bonds.
• General market risks, including suspension of trading on major exchanges (Frankfurt, London, New York), banking activities, or securities settlement/clearance systems, could impact the closing and settlement of the transactions.
• Outbreaks or escalation of hostilities, acts of terrorism, or declarations of national emergency/war could materially prejudice the placement and settlement of shares/bonds.
• Material adverse changes in financial, political, or economic conditions, currency exchange rates, or exchange controls could negatively affect the transactions.
• Undisclosed pending or threatened legal proceedings, actions, or suits against Fresenius KGaA or the Fresenius Group could have a Material Adverse Effect.
• Non-compliance with applicable Sanctions, Money Laundering Laws, or Anti-Bribery and Anti-Corruption Laws could lead to adverse consequences.
• Failure to maintain sufficient working capital for at least 12 months could impact the Issuer's financial stability.

Future Outlook

Fresenius KGaA does not currently anticipate a further reduction in its holdings in Fresenius Medical Care AG, but reserves the right to change its plans at any time, subject to market conditions or legal and regulatory requirements. The transactions are explicitly stated to enhance strategic flexibility and improve financial stability by strengthening the balance sheet and reducing leverage.

Management Comments

• "Fresenius KGaA is entering into these transactions as part of its #FutureFresenius strategy, with the goal of optimizing its portfolio of investment holdings to achieve structural simplification, consistent with the deconsolidation of the Company from the Fresenius KGaA consolidated group."
• "In addition, these transactions are intended to enhance Fresenius KGaA's strategic flexibility and improve its financial stability, by further strengthening the balance sheet and reducing leverage."
• "Following the completion of these transactions, Fresenius will remain the largest shareholder of FME."
• "Fresenius KGaA does not currently anticipate a further reduction in its holdings in the Company. However, it reserves the right to change its plans at any time, as it deems appropriate, or as the need arises, with any such decision subject to market conditions or legal and regulatory requirements."

Industry Context

This announcement aligns with a broader trend observed in the healthcare and diversified industrial sectors, where large conglomerates are streamlining their portfolios to focus on core businesses, enhance operational efficiency, and improve financial structures. The deconsolidation of Fresenius Medical Care AG from Fresenius KGaA's consolidated group, a previously disclosed strategic move, is a key part of this trend, allowing both entities more focused management and financial independence. This strategic shift is often driven by investor demand for clearer business models and improved capital allocation.

Corporate Governance

Legal Proceedings

• The document states that, other than as publicly disclosed, there are no pending or threatened legal proceedings, actions, or suits against Fresenius KGaA or the Fresenius Group that would have a Material Adverse Effect or directly relate to the Placement.
• It defines 'Event of Default' conditions, including if any Capital Market Indebtedness of Fresenius KGaA or a Material Subsidiary becomes prematurely repayable due to a default, or if payment obligations exceeding EUR 75,000,000 are not met within 30 days.

Related Party Transactions

• The core transactions involve Fresenius SE & Co. KGaA selling shares and issuing exchangeable bonds of its subsidiary, Fresenius Medical Care AG, which constitutes a related party transaction aimed at portfolio optimization and deconsolidation.

Stakeholder Impact

• **Shareholders (Fresenius KGaA)**: Expected to benefit from improved financial stability, reduced leverage, and enhanced strategic flexibility due to portfolio optimization.
• **Shareholders (Fresenius Medical Care AG)**: Fresenius KGaA will remain the largest shareholder, providing a degree of stability. However, the share placement and potential future conversion of exchangeable bonds could lead to increased float and potential dilution.
• **Creditors (Fresenius KGaA)**: Expected to benefit from a strengthened balance sheet and reduced leverage, potentially improving the company's credit profile.
• **Employees**: No direct impact on employees is mentioned in the filing, but strategic restructuring can sometimes lead to operational adjustments in the long term.
• **Customers/Suppliers**: No direct impact on customers or suppliers is indicated by these financial transactions.

Next Steps

• Closing of the Share Placement is expected on March 6, 2025.
• Closing of the Exchangeable Bond Offering is expected on March 11, 2025.
• The Exchangeable Bonds will be admitted to trading on the Open Market (Freiverkehr) segment of the Frankfurt Stock Exchange within one month after the closing date.
• Bondholders will be able to exchange their Exchangeable Bonds for shares during specified contingent exchange periods, starting from April 21, 2025, and from September 11, 2027.
• Fresenius KGaA is subject to a 180-day lock-up undertaking, restricting further dispositions of Fresenius Medical Care AG shares, subject to certain exceptions.

Key Dates

Recommendation

Keywords

Fresenius SE & Co. KGaA, Fresenius Medical Care AG, Share Placement, Exchangeable Bonds, Portfolio Optimization, Balance Sheet Strengthening, Leverage Reduction, Strategic Flexibility, Deconsolidation, Private Placement, SEC Filing, Schedule 13D/A, Corporate Strategy, Healthcare Industry, Germany